CLDI PE Ratio & Valuation, Is CLDI Overvalued

Historical Valuation

Calidi Biotherapeutics Inc (CLDI) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.27. The fair price of Calidi Biotherapeutics Inc (CLDI) is between -- to -- according to relative valuation method.

Relative Value

Fair Zone

-----

Current Price：0.37

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Calidi Biotherapeutics Inc (CLDI) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Calidi Biotherapeutics Inc (CLDI) has a current Price-to-Book (P/B) ratio of 1.20. Compared to its 3-year average P/B ratio of -11.74, the current P/B ratio is approximately -110.25% higher. Relative to its 5-year average P/B ratio of -21.66, the current P/B ratio is about -105.56% higher. Calidi Biotherapeutics Inc (CLDI) has a Forward Free Cash Flow (FCF) yield of approximately -252.09%. Compared to its 3-year average FCF yield of -146.03%, the current FCF yield is approximately 72.63% lower. Relative to its 5-year average FCF yield of -108.37%, the current FCF yield is about 132.62% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for CLDI competitors is 5.29, providing a benchmark for relative valuation. Calidi Biotherapeutics Inc Corp (CLDI.A) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of CLDI increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of CLDI in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is CLDI currently overvalued or undervalued?

What is Calidi Biotherapeutics Inc (CLDI) fair value?

CLDI's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Calidi Biotherapeutics Inc (CLDI) is between to according to relative valuation method.

How does CLDI's valuation metrics compare to the industry average?

The average P/S ratio for CLDI's competitors is 5.29, providing a benchmark for relative valuation. Calidi Biotherapeutics Inc Corp (CLDI) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Calidi Biotherapeutics Inc (CLDI) as of Mar 07 2026?

As of Mar 07 2026, Calidi Biotherapeutics Inc (CLDI) has a P/B ratio of 1.20. This indicates that the market values CLDI at 1.20 times its book value.

What is the current FCF Yield for Calidi Biotherapeutics Inc (CLDI) as of Mar 07 2026?

As of Mar 07 2026, Calidi Biotherapeutics Inc (CLDI) has a FCF Yield of -252.09%. This means that for every dollar of Calidi Biotherapeutics Inc's market capitalization, the company generates -252.09 cents in free cash flow.

What is the current Forward P/E ratio for Calidi Biotherapeutics Inc (CLDI) as of Mar 07 2026?

As of Mar 07 2026, Calidi Biotherapeutics Inc (CLDI) has a Forward P/E ratio of -0.20. This means the market is willing to pay $-0.20 for every dollar of Calidi Biotherapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Calidi Biotherapeutics Inc (CLDI) as of Mar 07 2026?

As of Mar 07 2026, Calidi Biotherapeutics Inc (CLDI) has a Forward P/S ratio of 0.00. This means the market is valuing CLDI at $0.00 for every dollar of expected revenue over the next 12 months.

CLDI Valuation